MYNOVOCURE Trademark
MYNOVOCURE is a USPTO trademark filed by Novocure GmbH. Status: Registered.
Trademark Facts
| Mark | MYNOVOCURE |
|---|---|
| Serial Number | 97683297 |
| Registration Number | 7415304 |
| Status | Registered |
| Filing Date | 2022-11-18 |
| Registration Date | 2024-06-11 |
| Mark Type | Word |
| Nice Classes | 035 (Advertising & Business), 036 (Financial Services), 041 (Education & Entertainment) |
| Owner | Novocure GmbH |
| Attorney of Record | Hara K. Jacobs |
| Prosecution Events | 26 |
| Latest Event | R.PR on 2024-06-11 |
Goods & Services
Medical educational services, namely, providing individualized and group instruction in the nature of training, classes, seminars and conferences for patients requiring treatment of solid tumor cancers and caregivers of patients requiring treatment of solid tumor cancers in the field of therapies and patient support for cancer treatment; educational services, providing of training and education, namely, providing information to caregivers in the areas of patient support services and information about therapies for cancer treatment, all of the aforesaid provided via telephone, e-learning and personal training sessions, and non-downloadable webinars and printed material distributed in connection therewith; Providing information about the financial administration of patient reimbursement programs designed to assist patients requiring treatment of solid tumor cancers regarding medical treatment payment plan options; providing patient support services, namely, providing insurance information to help patients requiring treatment of solid tumor cancers to understand their insurance and plan benefits and providing insurance reimbursement assistance to eligible patients; Providing information about the business administration of patient reimbursement programs designed to assist patients requiring treatment of solid tumor cancers regarding medical treatment payment plan options; providing business administration assistance to patients requiring treatment of solid tumor cancers regarding treatment payment plan options, namely, administration of patient reimbursement programs for patients requiring treatment of solid tumor cancers